B
UTHR icon

Barings’s United Therapeutics UTHR Stock Holding History

Barings’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,590
Closed -$207K – 684
2019
Q3 		$207K Hold
2,590
– – ﹤0.01% 626
2019
Q2 		$202K Sell
2,590
-4,450
-63% -$416K ﹤0.01% 653
2019
Q1 		$826K Hold
7,040
– – 0.02% 433
2018
Q4 		$767K Buy
7,040
+2,450
+53% +$284K 0.01% 432
2018
Q3 		$587K Hold
4,590
– – 0.01% 593
2018
Q2 		$519K Buy
4,590
+2,140
+87% +$235K 0.01% 638
2018
Q1 		$275K Hold
2,450
– – ﹤0.01% 832
2017
Q4 		$362K Sell
2,450
-1,700
-41% -$216K ﹤0.01% 794
2017
Q3 		$486K Hold
4,150
– – 0.01% 655
2017
Q2 		$538K Sell
4,150
-15,190
-79% -$1.89M 0.02% 606
2017
Q1 		$2.62M Buy
19,340
+9,670
+100% +$1.46M 0.03% 519
2016
Q4 		$1.39M Hold
9,670
– – 0.03% 373
2016
Q3 		$1.14M Sell
9,670
-7,400
-43% -$889K 0.03% 409
2016
Q2 		$1.81M Buy
17,070
+3,300
+24% +$368K 0.05% 331
2016
Q1 		$1.53M Hold
13,770
– – 0.04% 370
2015
Q4 		$2.16M Buy
13,770
+10,640
+340% +$1.55M 0.05% 271
2015
Q3 		$411K Sell
3,130
-5,140
-62% -$824K 0.01% 682
2015
Q2 		$1.44M Buy
8,270
+2,360
+40% +$425K 0.04% 403
2015
Q1 		$1.02M Hold
5,910
– – 0.02% 502
2014
Q4 		$765K Hold
5,910
– – 0.02% 545
2014
Q3 		$760K Sell
5,910
-17,180
-74% -$1.77M 0.02% 549
2014
Q2 		$2.04M Buy
23,090
+11,100
+93% +$1.07M 0.06% 313
2014
Q1 		$1.13M Buy
11,990
+690
+6% +$70.6K 0.04% 429
2013
Q4 		$1.28M Buy
11,300
+1,400
+14% +$126K 0.05% 363
2013
Q3 		$781K Sell
9,900
-5,900
-37% -$431K 0.03% 489
2013
Q2 		$1.04M Buy
+15,800
New +$1.02M 0.05% 396

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Barings's UTHR Position: Q4 2019 in Review

Barings sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 2,590 shares — an estimated $207K sold.

Barings first reported a position in UTHR in Q2 2013 and held it in 26 quarters. The position peaked at $2.62M in Q1 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

  • Barings reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Barings sold 2,590 United Therapeutics shares in Q4 2019, an estimated $207K.
  • Barings first reported a position in United Therapeutics in Q2 2013 and held it in 26 quarters.
  • Barings's United Therapeutics position peaked at $2.62M in Q1 2017.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Barings's 13F filing for Q4 2019, filed 14 Feb 2020.